AgingResearch.NewsJoin free

Guangrong Zheng

Works at

Sources: reporter.nih.gov

Grants and prizes

  • National Cancer Institute

    R01, Inhibition of Bcl-xL by Targeted Degradation, R01CA241191, 2020–2026, 22 Mar 2024

  • National Cancer Institute

    R01, Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer, R01CA242003, 2019–2024, 30 Aug 2023

  • National Institute on Aging

    R01, Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics, R01AG063801, 2019–2025, 8 Mar 2023

Sources: reporter.nih.gov